Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
38 hedge funds and large institutions have $4.34M invested in Navidea Biopharmaceuticals Inc. in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
7% more call options, than puts
Call options by funds: $397K | Put options by funds: $372K
7% less funds holding
Funds holding: 41 → 38 (-3)
28% less capital invested
Capital invested by funds: $6.01M → $4.34M (-$1.68M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$251K |
| 3 |
Two Sigma Advisers
New York
|
+$147K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$130K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$548K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$413K |
| 3 |
OFG
OTA Financial Group
Purchase,
New York
|
-$258K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$168K |
| 5 |
Two Sigma Investments
New York
|
-$79.9K |
NAVB Hedge Fund Activity: Q3 2020 in Review
38 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2020, worth a combined $4.34M — down 28% from $6.01M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NAVB and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $1.19M. The largest seller was Renaissance Technologies, cutting an estimated $548K.
- 38 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2020, down from 41 in Q2 2020.
- Funds reported $4.34M of Navidea Biopharmaceuticals Inc. stock for Q3 2020, down 28% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2020 and 8 closed out, a net change of -3 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2020 was Vanguard Group, an estimated $1.19M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2020 was Renaissance Technologies, an estimated $548K sold.
Based on aggregated 13F filings for Q3 2020.